ArticleJACC. Case reports2026
Multidisciplinary Management of a Rare Primary Cardiac Angiosarcoma.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary Pulmonary Angiosarcoma: Case Report and Literature Review.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary cardiac tumors are exceptionally rare, with an autopsy incidence of only 0.001% to 0.03%. Angiosarcoma represents the most common subtype of cardiac sarcomas, which account for approximately 95% of malignant cases. CASE SUMMARY: A 30-year-old woman presented with chest tightness and dyspnea. Imaging revealed a 65 × 47 mm right atrial mass. She underwent complete surgical resection, with pathology confirming intimal sarcoma. Adjuvant paclitaxel/cisplatin chemotherapy was administered. Short-term follow-up showed no recurrence or metastasis. DISCUSSION: Cardiac angiosarcoma remains a therapeutic challenge with poor prognosis, necessitating multimodal management centered on complete surgical resection and adjuvant chemotherapy. Diagnosis relies heavily on advanced imaging, while definitive confirmation requires histopathological examination. Future research should prioritize targeted therapies and immunotherapies, supported by international collaboration to improve outcomes for this rare malignancy. TAKE-HOME MESSAGE: This case demonstrates that early diagnosis, complete resection, and adjuvant chemotherapy are crucial for managing this highly lethal disease with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.